This study aims to find out if *guselkumab* (a selective IL23 inhibitor) works better than *golimumab* (another TNF inhibitor) for patients with psoriatic arthritis (PsA) who didn't respond well to a previous TNF inhibitor. Psoriatic arthritis is a type of arthritis that affects some people who have the skin condition psoriasis. *Tumor necrosis factor inhibitors* (TNFi) are drugs that help reduce inflammation but sometimes don't work for everyone. This study is open-label, meaning both the doctors and patients know which treatment is being given.

To join, participants must be aged 18-80 and have active PsA. They should have used a TNFi before and not responded well. If they are using other medications like methotrexate or NSAIDs, they need to be on a stable dose.

• Study Duration: Length not specified but involves multiple visits.
• Treatments Being Tested: Guselkumab vs. Golimumab.
• Risks: Must not have prior exposure to certain drugs or severe reactions to TNF inhibitors.